Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Third and fourth generation fluoroquinolones].

C Rossi1, J Sternon

  • 1Service des Maladies Infectieuses, Réseau Hospitalier de Médecine Sociale, Sites d'Ath, Baudour et Tournai.

Revue Medicale De Bruxelles
|November 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of postnatal growth in very low birth weight infants: a neonatologist's dilemma.

Pediatric endocrinology reviews : PER·2008
Same author

A combinated approach to investigate the biochemistry and hydrography of a shallow bay in the south Adriatic Sea: the Gulf of Manfredonia (Italy).

Environmental monitoring and assessment·2008
Same author

Early linezolid-associated lactic acidosis in a patient treated for tuberculous spondylodiscitis.

Infection·2008
Same author

Use of netilmicin once or twice daily in preterm newborns: evaluation of nephrotoxicity by urinary alpha1-microglobulin and retinol binding protein.

Journal of chemotherapy (Florence, Italy)·2008
Same author

Ferritin iron content in haemodialysis patients: comparison with septic and hemochromatosis patients.

Clinical biochemistry·2008
Same author

Effects of the aromatase inhibitor letrozole on in utero development in rats.

Human reproduction (Oxford, England)·2008
Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018
Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018
Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018
Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018
Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018
Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018
See all related articles

Newer fluoroquinolones (FQs) show improved efficacy against respiratory pathogens like S. pneumoniae. While generally safe, some FQs have been withdrawn due to toxicity. Careful use of these important antibiotics is crucial to prevent bacterial resistance.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Bacteriology

Background:

  • Levofloxacin, a third-generation fluoroquinolone (FQ3G), is effective against S. pneumoniae.
  • Fourth-generation fluoroquinolones (FQ4G) exhibit broad-spectrum activity against respiratory pathogens, including Gram-positive cocci.
  • FQ4G offer convenient once-daily oral administration due to their prolonged serum bactericidal levels.

Purpose of the Study:

  • To evaluate the efficacy and safety of third- and fourth-generation fluoroquinolones (FQs) for respiratory infections.
  • To discuss the clinical positioning of FQ3G and FQ4G in community-acquired pneumonia (CAP) management.
  • To highlight the importance of judicious antibiotic prescribing to mitigate the development of bacterial resistance.

Main Methods:

Related Experiment Videos

  • Review of in vitro activity data for FQ3G and FQ4G against common respiratory pathogens.
  • Analysis of clinical data regarding efficacy, safety profiles, and adverse events associated with FQ use.
  • Discussion of current treatment guidelines and empirical therapy for community-acquired pneumonia.

    • Main Results:

    • FQ4G demonstrate enhanced in vitro activity against Gram-positive bacteria, particularly S. pneumoniae.
    • Adverse effects of FQs are primarily gastrointestinal, neurological, or cutaneous.
    • Several FQ4G were withdrawn in the US due to severe toxicity; others are emerging as therapeutic options.

    Conclusions:

    • Newer FQs are valuable therapeutic options for community-acquired pneumonia, especially in penicillin-allergic or debilitated patients, or when resistant S. pneumoniae is suspected.
    • Judicious use of FQs is essential to prevent the emergence of antibiotic resistance, particularly in S. pneumoniae.
    • The role of FQ3G and FQ4G in respiratory infections requires ongoing evaluation and careful clinical application.